ProKidney shares surge 11.78% intraday after CEO announces presentation at J.P. Morgan Healthcare Conference.

ProKidney Corp. (Nasdaq: PROK) surged 11.78% intraday after announcing that its CEO, Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company also highlighted one-on-one meetings with investors during the event, signaling heightened visibility and engagement. As a late-stage cell therapy developer for chronic kidney disease, ProKidney’s participation in a high-profile conference likely boosted investor optimism about its pipeline progress and commercial potential. The announcement aligns with the stock’s intraday rally, reflecting market anticipation of strategic updates or partnerships. Earlier media sentiment referencing a prior decline is unrelated to the current move.